
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
San Francisco ?? Dermatologists might find it strange when patients come into their offices complaining of nearly invisible "scars" or other imperfections. Yet the patients focus on the flaws to the point that one would think they were dominant features.